| Domino's Pizza Enterprises Limited (DMP) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,839 |
FY25 Appendix 4G
|
27 Aug 2025 8:19AM |
$19.360 |
$19.410 |
risen by
0.26%
|
|
| Domino's Pizza Enterprises Limited (DMP) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,839 |
FY25 Corporate Governance Statement
|
27 Aug 2025 8:19AM |
$19.360 |
$19.410 |
risen by
0.26%
|
|
| COG Financial Services Limited (COG) ORDINARY FULLY PAID |
Financials |
$310 |
Appendix 4G and Corporate Governance Statement
|
27 Aug 2025 8:18AM |
$1.800 |
$1.455 |
fallen by
19.17%
|
|
| Ashley Services Group Limited (ASH) ORDINARY FULLY PAID |
Industrials |
$42 |
Appendix 4E and Annual Report
|
27 Aug 2025 8:18AM |
$0.180 |
$0.280 |
risen by
55.56%
|
|
ASH - Price-sensitive ASX Announcement
Full Release
Key Points
- Ashley Services Group Limited (ASH) released its Appendix 4E and Annual Report for the year ended 30 June 2023.
- The Group reported a statutory net profit after tax (NPAT) of $8.7 million, up from $7.6 million in the previous year.
- Revenue increased to $437.3 million from $430.4 million in the prior year.
- The Board declared a fully franked final dividend of 1.2 cents per share, bringing the total dividend for the year to 2.2 cents per share, fully franked.
- Operating cash flow for the year was $15.9 million, and the Group maintained a strong balance sheet, finishing the year with $38.1 million in cash and no debt.
- The Group’s business consists of Labour Hire, Recruitment Services, and Training Services, with Labour Hire being the largest contributor by revenue.
- The company made progress in diversifying its client base and services, including growth in blue-collar and white-collar sectors.
- Ashley Services Group Limited continues to prioritize risk management, compliance, and robust corporate governance.
- The Group is focused on disciplined cost management and investing in technology to enhance operational efficiency.
- Market conditions remain competitive, but the company is positioned for continued growth and shareholder value creation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Domino's Pizza Enterprises Limited (DMP) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,839 |
Dividend Reinvestment Plan
|
27 Aug 2025 8:18AM |
$19.360 |
$19.410 |
risen by
0.26%
|
|
DMP - Price-sensitive ASX Announcement
Full Release
Key Points
- Domino's Pizza Enterprises Limited (DMP) announced the establishment of a Dividend Reinvestment Plan (DRP).
- The DRP allows eligible shareholders to reinvest all or part of their dividends in additional fully paid ordinary shares in DMP instead of receiving cash.
- Participation in the DRP is optional and open to shareholders with registered addresses in Australia and New Zealand, subject to certain exclusions.
- Shares allotted under the DRP will rank equally with existing shares and may be issued at a discount determined by the Board.
- Shareholders can participate fully or partially and may vary or terminate their participation according to DRP rules.
- The DRP will be administered by the Board, which retains discretion over the operation and terms of the DRP.
- Any dispute regarding the DRP will be determined by the Board, whose decision is final.
- Shares issued or transferred under the DRP will be quoted on the ASX.
- The Board may modify, suspend, or terminate the DRP at any time, subject to ASX Listing Rules.
- Participation in the DRP will not incur brokerage, commission, or transaction costs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Domino's Pizza Enterprises Limited (DMP) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,839 |
FY25 Full-Year Media Release
|
27 Aug 2025 8:18AM |
$19.360 |
$19.410 |
risen by
0.26%
|
|
DMP - Price-sensitive ASX Announcement
Full Release
Key Points
- Domino's Pizza Enterprises Limited released its FY25 Full-Year Results on 21 August 2024.
- The report details group sales, EBITDA, and net profit after tax.
- Challenging market conditions were noted in Australia, New Zealand, and parts of Europe.
- Positive sales growth was achieved in Japan and several European countries.
- The company continued to focus on digital transformation and menu innovation.
- Disciplined cost management and operational efficiency initiatives were emphasized.
- Network expansion included new store openings, especially in Japan and Europe.
- Supply chain pressures and inflation impacted costs and profitability.
- The company outlined its strategic focus for FY25, including margin improvement and customer value.
- A transformation program was underway to modernize operations and improve the customer experience.
- Outlook for FY25 includes continued investment in digital, menu, and network initiatives.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Domino's Pizza Enterprises Limited (DMP) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,839 |
FY25 Full-Year Market Presentation
|
27 Aug 2025 8:17AM |
$19.360 |
$19.410 |
risen by
0.26%
|
|
DMP - Price-sensitive ASX Announcement
Full Release
Key Points
- DMP presented its FY25 full-year market update on June 12, 2024.
- The company emphasized its strategic focus on customer experience, operational efficiency, and technological advancement.
- Store network expansion and digital sales channels are key pillars for future growth.
- Menu innovation and disciplined cost control are targeted to enhance value and profitability.
- DMP provided updates on its international operations and regional performance.
- Financial performance targets and metrics were communicated in line with long-term growth ambitions.
- Challenges such as changing consumer behavior, inflationary costs, and competitive markets were acknowledged.
- The company remains confident in its adaptability and growth strategy for FY25 and beyond.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Domino's Pizza Enterprises Limited (DMP) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,839 |
FY25 Appendix 4E / Annual Report
|
27 Aug 2025 8:17AM |
$19.360 |
$19.410 |
risen by
0.26%
|
|
DMP - Price-sensitive ASX Announcement
Full Release
Key Points
- Reports on financial performance for FY24, including revenue, net profit, and same-store sales.
- Highlights digital innovation as a core driver of operational efficiency and customer engagement.
- Details ongoing market expansion plans, with a focus on new store openings and franchisee support.
- Discusses responses to operational challenges, including cost management and supply chain improvements.
- Emphasizes sustainability initiatives and corporate governance as key business priorities.
- Presents outlook for FY25 centered on technology investment, market growth, and strengthening stakeholder relationships.
- Notes challenges in certain regions but maintains a positive growth outlook.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| COG Financial Services Limited (COG) ORDINARY FULLY PAID |
Financials |
$310 |
Appendix 4E, Audited Financial Statements and Annual Report
|
27 Aug 2025 8:17AM |
$1.800 |
$1.455 |
fallen by
19.17%
|
|
COG - Price-sensitive ASX Announcement
Full Release
Key Points
- COG Financial Services Limited released its Appendix 4E, Audited Financial Statements, and Annual Report for the year ended 30 June 2023.
- The company operates in asset finance broking, insurance broking, and funds management for small to medium businesses.
- Revenue and net profit after tax increased compared to the previous year, reflecting strong operating performance and successful acquisitions.
- The business model emphasizes both organic growth and growth through strategic acquisitions.
- Segment performance analysis highlights robust results in finance broking and funds management, with positive contributions from recent business integrations.
- The company maintains a focus on risk management, compliance, and strong corporate governance.
- Management commentary outlines the economic environment, strategic priorities, and ongoing commitment to stakeholder value.
- The financial statements provide a detailed breakdown of revenue, expenses, assets, liabilities, and cash flows.
- Auditor’s report confirms the financial statements give a true and fair view of the financial position as at 30 June 2023.
- The document includes disclosures required under statutory and regulatory frameworks, demonstrating transparency and accountability.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Epsilon Healthcare Limited (EPN) ORDINARY FULLY PAID |
Health Care |
$9 |
Company Secretary Appointment/Resignation
|
27 Aug 2025 8:17AM |
$0.024 |
$0.022 |
fallen by
8.33%
|
|
| Sigma Healthcare Limited (SIG) ORDINARY FULLY PAID |
Health Care |
$34,400 |
Management Succession
|
27 Aug 2025 8:17AM |
$2.820 |
$2.980 |
risen by
5.67%
|
|
| Sigma Healthcare Limited (SIG) ORDINARY FULLY PAID |
Health Care |
$34,400 |
Sigma Full Year FY25 Results Presentation
|
27 Aug 2025 8:17AM |
$2.820 |
$2.980 |
risen by
5.67%
|
|
SIG - Price-sensitive ASX Announcement
Full Release
Key Points
- Sigma Healthcare Limited's merger with CW Group increased revenue and EBIT significantly.
- The company achieved a normalised revenue of $6 billion, up 82%.
- EBIT increased by 41% to $834.5 million.
- The merger completion in February 2025 facilitated financial performance improvements.
- Sigma's growth strategy includes expanding its retail network and improving product mix.
- Over 20% growth in sales of own and exclusive label products was achieved.
- Operational efficiencies and synergies are projected to reach $100 million annually by year four.
- FY26 outlook includes continued revenue growth and operational enhancements.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sigma Healthcare Limited (SIG) ORDINARY FULLY PAID |
Health Care |
$34,400 |
Sigma Full Year FY25 Results Presentation
|
27 Aug 2025 8:17AM |
$2.820 |
$2.980 |
risen by
5.67%
|
|
SIG - Price-sensitive ASX Announcement
Full Release
Key Points
- Sigma Healthcare revenue up 82% to $6 billion.
- EBIT increased by 41% to $834.5 million.
- Pro-forma numbers assume full merger effect from July 1, 2024.
- New $1.5 billion debt facility secured until 2028.
- Net debt to normalized EBITDA ratio of 0.85x.
- CWG's PBS volumes onboarded from July 2024.
- Synergy target revised to $100 million.
- Sigma's retail network expanded in domestic and international markets.
- Over 260 Wagner health generic medicines launched.
- Sigma emerges stronger post-merger with increased scale and capabilities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sigma Healthcare Limited (SIG) ORDINARY FULLY PAID |
Health Care |
$34,400 |
Sigma Full Year FY25 ASX Release
|
27 Aug 2025 8:17AM |
$2.820 |
$2.980 |
risen by
5.67%
|
|
SIG - Price-sensitive ASX Announcement
Full Release
Key Points
- Normalised EBIT up 41.4%, Pro-forma EBIT of $903.4 million.
- Merger with Chemist Warehouse Group enhances scale and market reach.
- Total retail network sales up 14% to $10.3 billion.
- Synergy target upgraded to $100 million per annum.
- Year-end net debt of $752.2 million.
- Strong operating cash flow of $598.8 million.
- Dividend of 1.3 cps declared, payable on 18 September 2025.
- Own and exclusive brand strategy accelerated.
- Progressive conversion of MyChemist pharmacies to Amcal and Discount Drug Stores.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sigma Healthcare Limited (SIG) ORDINARY FULLY PAID |
Health Care |
$34,400 |
Sigma Full Year FY25 ASX Release
|
27 Aug 2025 8:17AM |
$2.820 |
$2.980 |
risen by
5.67%
|
|
SIG - Price-sensitive ASX Announcement
Full Release
Key Points
- Merger with CWG Holdings boosted sales growth.
- Retail network sales reached $10.3 billion, up 14%.
- New Zealand sales exceeded A$1.0 billion.
- Onboarded CWG medicine supply contract, adding $2.0 billion revenue.
- Delivery volumes increased by 29% to 532 million units.
- Reduced cost to serve per unit by 11% through automation.
- Launched 269 Wagner generics medicines.
- Sales of exclusive label products up 20%.
- Synergy target increased to $100 million per annum.
- Year-end net debt was $752.2 million.
- Strong operating cash flow of $598.8 million.
- Declared a dividend of 1.3 cents per share.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sigma Healthcare Limited (SIG) ORDINARY FULLY PAID |
Health Care |
$34,400 |
Appendix 4E & Full Year Financial Report
|
27 Aug 2025 8:16AM |
$2.820 |
$2.980 |
risen by
5.67%
|
|
SIG - Price-sensitive ASX Announcement
Full Release
Key Points
- Significant decrease in revenue by 94% compared to the previous year.
- Net loss of AUD 4.94 million for the fiscal year ending 30 June 2025.
- Focus on commercialising the Felix™ System for assisted reproductive technology.
- Increased operational costs in research and development and marketing.
- Strategic shift towards building market presence and securing regulatory approvals.
- Emphasis on driving early revenues and establishing sustainable sales channels.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AdAlta Limited (1AD) ORDINARY FULLY PAID |
Health Care |
$10 |
Appendix 4G and Corporate Governance Statement
|
27 Aug 2025 8:16AM |
$0.004 |
$0.003 |
fallen by
25%
|
|
| Sigma Healthcare Limited (SIG) ORDINARY FULLY PAID |
Health Care |
$34,400 |
Appendix 4E & Full Year Financial Report
|
27 Aug 2025 8:16AM |
$2.820 |
$2.980 |
risen by
5.67%
|
|
SIG - Price-sensitive ASX Announcement
Full Release
Key Points
- Merger between Sigma Healthcare Limited and Chemist Warehouse completed on 12 February 2025.
- Sales revenue increased by 82.3% to $6 billion.
- Normalised EBIT reported at $834.5 million, a 41.4% increase.
- Gross margin decreased to 24% from 31.7% due to merger costs.
- Net profit after tax attributable to owners of $529.9 million.
- Significant investment in goodwill and intangible assets post-merger.
- Cash flow from operations improved, though impacted by merger-related distributions.
- Integration of Sigma and Chemist Warehouse operations across multiple regions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AdAlta Limited (1AD) ORDINARY FULLY PAID |
Health Care |
$10 |
Annual Report to shareholders
|
27 Aug 2025 8:16AM |
$0.004 |
$0.003 |
fallen by
25%
|
|
| Cuscal Limited (CCL) ORDINARY FULLY PAID |
Financials |
$1,087 |
Appendix 3Y E Proust
|
27 Aug 2025 8:16AM |
$3.520 |
$5.440 |
risen by
54.55%
|
|
| AdAlta Limited (1AD) ORDINARY FULLY PAID |
Health Care |
$10 |
Preliminary Final Report
|
27 Aug 2025 8:16AM |
$0.004 |
$0.003 |
fallen by
25%
|
|
1AD - Price-sensitive ASX Announcement
Full Release
Key Points
- AdAlta Limited is focused on developing i-body platform therapeutics, particularly AD-214 for fibrotic diseases.
- The company completed all cohorts of the Phase I extension study for AD-214.
- Progress was made in manufacturing process development to support further clinical trials.
- Preclinical pipeline was expanded, notably in radiopharmaceuticals for oncology and fibrosis.
- AdAlta maintained a strategy of prudent cash management and continued seeking partnerships and funding.
- A net loss was reported for the year, reflecting R&D and operational investments.
- The report emphasizes significant clinical and corporate advancements during the period.
- AdAlta is positioning itself for further growth in the biotechnology sector.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pointsbet Holdings Limited (PBH) ORDINARY FULLY PAID |
Consumer Discretionary |
$308 |
Change in substantial holding
|
27 Aug 2025 8:16AM |
$1.250 |
$0.885 |
fallen by
29.20%
|
|
| Patagonia Lithium Ltd (PL3) ORDINARY FULLY PAID |
Materials |
$24 |
Notice of change of interests of substantial holder
|
27 Aug 2025 8:16AM |
$0.038 |
$0.100 |
risen by
163.16%
|
|
| Latitude Group Holdings Limited (LFS) ORDINARY FULLY PAID |
Financials |
$941 |
Update - Notification of buy-back - LFSPA
|
27 Aug 2025 8:16AM |
$1.130 |
$0.905 |
fallen by
19.91%
|
|
| Clever Culture Systems Limited (CC5) ORDINARY FULLY PAID |
Health Care |
$33 |
APAS Contact Plate Application Product Launch
|
27 Aug 2025 8:16AM |
$0.035 |
$0.015 |
fallen by
57.14%
|
|
CC5 - Price-sensitive ASX Announcement
Full Release
Key Points
- Clever Culture Systems Limited (CCS) is a joint venture involving HiberGene Diagnostics, SARSTEDT, and bioMérieux.
- On 5 June 2024, CCS announced the launch of the APAS Contact Plate Application.
- The APAS Contact Plate Application automates the imaging, analysis, and interpretation of environmental contact plates.
- The application is targeted for use in cleanroom environments, such as pharmaceutical manufacturing and healthcare settings.
- It employs artificial intelligence to detect microbial growth and classify colonies.
- The product aims to enhance laboratory efficiency, accuracy, and regulatory compliance.
- The launch reinforces CCS’s position as an innovator in laboratory automation for microbiology.
- Supports digital transformation trends in clinical and manufacturing microbiology.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
